Mandi J Corenblum1, Andrew J Flores1,2, Michael Badowski3, David T Harris3, Lalitha Madhavan1. 1. Department of Neurology, University of Arizona, 1501, N Campbell Ave., Tucson, AZ 85724, USA. 2. Physiological Sciences Graduate Program, University of Arizona, Tucson, AZ 85724, USA. 3. Department of Immunobiology, University of Arizona, Tucson, AZ 85724-5221, USA.
Abstract
AIM: Here we investigated the neuroprotective potential of systemic CD34(+) human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson's disease. METHODS: Purified CD34(+) hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. RESULTS: CD34(+) hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donor hCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donor hCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. CONCLUSION: Peripherally applied CD34(+) hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.
AIM: Here we investigated the neuroprotective potential of systemic CD34(+) human cord blood cells (hCBCs) in a 6-hydroxydopaminerat model of Parkinson's disease. METHODS: Purified CD34(+) hCBCs were intravenously administered to rats subjected to 6-hydroxydopamine 24 h earlier, and behavioral and immunohistological analysis performed. RESULTS:CD34(+) hCBC administration significantly prevented host nigrostriatal degeneration inducing behavioral recovery in treated rats. Although donorhCBCs did not differentiate into neural phenotypes, they stimulated the production of new neuroblasts and angiogenesis, and reduced gliosis in recipient animals. Importantly, surviving donorhCBCs were identified, and their tissue distribution pattern correlated with the observed therapeutic effects. CONCLUSION: Peripherally applied CD34(+) hCBCs can migrate into brain tissues and elicit host-based protective mechanisms to support the survival of midbrain dopamine neurons.
Authors: S Ray; M J Corenblum; A Anandhan; A Reed; F O Ortiz; D D Zhang; C A Barnes; L Madhavan Journal: Cell Transplant Date: 2018-06-05 Impact factor: 4.064
Authors: Christopher R Apostol; Kelsey Bernard; Parthasaradhireddy Tanguturi; Gabriella Molnar; Mitchell J Bartlett; Lajos Szabò; Chenxi Liu; J Bryce Ortiz; Maha Saber; Katherine R Giordano; Tabitha R F Green; James Melvin; Helena W Morrison; Lalitha Madhavan; Rachel K Rowe; John M Streicher; Michael L Heien; Torsten Falk; Robin Polt Journal: Front Drug Discov (Lausanne) Date: 2022-01-14
Authors: Annadurai Anandhan; Nhat Nguyen; Arjun Syal; Luke A Dreher; Matthew Dodson; Donna D Zhang; Lalitha Madhavan Journal: Aging Dis Date: 2021-07-01 Impact factor: 6.745